Shares of Praxis Precision Medicines ( PRAX +13.25%) leaped on Monday after the clinical-stage biopharmaceutical company ...

Praxis Precision Medicines has won Food and Drug Administration breakthrough-therapy designation for its ulixacaltamide drug candidate for the treatment of patients with essential tremor.

The Breakthrough Therapy Designation was granted based on the positive topline results from the Essential3 Phase 3 program in ...

Novartis’ ITVISMA, approved a month ago by the US FDA, used at Sheikh Khalifa Medical City under the supervision of the ...

Phase 2 trial results showed an improvement in MASH with no worsening of fibrosis in all treatment groups compared with placebo. The Food and Drug Administration (FDA) has granted Breakthrough Therapy ...

Abu Dhabi marks landmark achievement in becoming the first in the world to deliver ITVISMA (onasemnogene abeparvovec) for the ...

Taysha Gene Therapies (TSHA) is back in focus after its Rett syndrome program hit several milestones at once, including FDA Breakthrough Therapy Designation for TSHA-102 and encouraging REVEAL study ...

AstraZeneca and Daiichi Sankyo’s Enhertu's breakthrough therapy designation as a post-neoadjuvant treatment option for ...

Investing.com -- Praxis Precision Medicines Inc (NASDAQ:PRAX) stock jumped 17.1% in Monday’s premarket trading after the company announced that the U.S. Food and Drug Administration (FDA) has granted ...

Breast cancer diagnosis is one of the most worrying in society, as thousands of women face this disease with uncertainty ...

The FDA granted Breakthrough Therapy status to Incyte's experimental treatment for a rare blood cancer. Incyte stock is basing near five-year highs.

There is no cure for the rare disease Hereditary Spastic Paraplegia (HSP), but researchers from Drexel University’s College ...